Abstract Details

Title Cytokines in the Central Disorders of Hypersomnolence

Topic Sleep

Presentation(s) Sleep Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 028

Background

Cytokines are known for their role in inflammation, and more recently in sleepiness and fatigue. There is a paucity of data regarding cytokines in Idiopathic Hypersomnia (IH) and Narcolepsy Type 2 (NT2) as defined by the International Classifications of Sleep Disorders-Third Edition. Additionally the heterogenous cohort of patients with excessive daytime sleepiness (EDS), but do not meet criteria for a sleep disorder, has not been studied separately from IH patients.

Objective Differentiate cytokine profiles in disorders of hypersomnolence

Design/Methods The study cohort was a convenience sample evaluated at a single tertiary-care sleep center between 2016 and 2019. Diagnoses were IH, NT2, EDS, and controls (based on sleep laboratory testing). The following cytokines were measured using the Mesoscale U-PLEX biomarker assay: G-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, MCP-1, and TNF-α. Demographic data and survey data pertaining to sleepiness, depression, and sleep inertia were available for all.

Results

The study cohort consisted of 22 controls, 26 patients with EDS, 51 patients with IH, and 12 patients with NT2. There were no significant differences between diagnosis and any cytokine. Stratified by gender, there was a significant difference in concentrations of IL-10 in men with EDS compared to controls (0.41 +/- 0.11 vs. 1.1 +/- 0.89, p = 0.039). Pearson correlations showed significant negative correlations between G-CSF concentrations with depression (p=0.05) and sleep inertia (p<0.01) in patients, but not controls. In controls, hours slept per week positively correlated with G-CSF (p=0.05), but this was not true in patients with EDS, IH, or NT2.

Conclusions

Though differences between diagnostic groups did not reach significance, the variability across diagnoses could represent an inflammatory fingerprint that could be used to categorize individuals who do not fit current diagnostic categories. G-CSF may serve as a biomarker for symptoms of depression and sleep inertia, and could be a target for therapies.

Authors/Disclosures
Caroline Maness, MD (Emory University SOM) PRESENTER	Dr. Maness has nothing to disclose.
LynnMarie Trotti, MD (Emory University School of Medicine)	Dr. Trotti has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for American Academy of Sleep Medicine. Dr. Trotti has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Association of Chest Physicians. The institution of Dr. Trotti has received research support from NIH. The institution of Dr. Trotti has received research support from American Academy of Sleep Medicine Foundation . Dr. Trotti has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with AASM, CHEST, Medscape, SRS Foundation, PER CME, Haymarket CME. Dr. Trotti has received personal compensation in the range of $0-$499 for serving as a DSMB member with NIH. Dr. Trotti has received personal compensation in the range of $0-$499 for serving as a Reviewer with Lancet journals. Dr. Trotti has a non-compensated relationship as a Medical advisory board member with Hypersomnia Foundation that is relevant to AAN interests or activities. Dr. Trotti has a non-compensated relationship as a Board member with AASM Foundation that is relevant to AAN interests or activities. Dr. Trotti has a non-compensated relationship as a Board member with ABSM that is relevant to AAN interests or activities.